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’INTRODUCTION
Theeﬀective,butsimultaneouslycheapandsimple,long-term
storage of proteins with complex function is essential in nano-
biotechnology (e.g., in the development of commercially viable
biosensors).However,thisisachallengingtaskwithconsiderable
variability among diﬀerent proteins, both in stability and in the
optimalstorage method.
1Moreover,themechanismsforprotein
deterioration/preservation during storage under diﬀerent con-
ditions are not fully understood even though conformational
instability,proteolyticdegradation,andmetal-ion-inducedoxida-
tion are of importance.
2
Thestorageofcomplexproteinnanomachinesimmobilizedat
artiﬁcial surfaces is of particular relevance to the biosensor ﬁeld
and surface immobilization might also increase protein stability
during storage (ref 3, see further below), but this idea requires
further exploration. The actomyosin motor system relies on
intact enzymatic function, actin polymerization, and actomyosin
bimolecular interactions, and it is sensitive to deterioration by
several mechanisms.
4 6 It should therefore be a critical test
system for investigations of functional changes during storage.
The actomyosin system is also of speciﬁc interest because
recent investigations have identiﬁed potential molecular-motor-
driven lab-on-a-chip applications (e.g., in diagnostics (cf. refs 7
and 8), periodic chemistry,
9 sorting,
10 12 and biosensing
13).
Such applications, where myosin- or kinesin-propelled cytoske-
letalﬁlaments(actinﬁlamentsormicrotubules)actasshuttlesfor
cargo transportation, have certain advantages compared to
microﬂuidic-driven transport.
7,14 This includes a greater poten-
tial for miniaturization and a unique approach to the concentra-
tion of analyte molecules and the separation of analyte-binding
and detection sites in diagnostics. In addition, molecular-motor
devices are self-sustained by the transduction of the chemical
energy of ATP directly into mechanical work, thereby circum-
ventingtheneedforexternalpowersupplies(e.g.,todrivepumps
for microﬂuidics). In this context, the actomyosin motor
system (compared to kinesin microtubules) has advantages
such as high speed (10 μm/s) and a greater potential for
miniaturization.
7,15,16
Previous studies on motor-driven nanodevices have focused
on technicallyadvanceddevelopments(e.g., guided transport on
nanostructured surfaces and approaches to cargo pick up and
transport by motor-driven shuttles
14,17,18). However, less atten-
tion has been devoted to the absolutely essential long-term
storage of the devices. Whereas some studies of microtubu-
le kinesin motor systems have used lyophilization
19,20 or cri-
tical-point drying,
20 studies on actomyosin have been limited to
theeﬀectsofstorageat4C,whichwasfoundtobepossiblefora
little more than a week.
21,22
On the basis of the idea that surface immobilization may have
certainstabilizingeﬀectsduringstorage,westudyheretheeﬀects
of freeze thaw cycles on the delicate motor function of acto-
myosin immobilized on silanized surfaces. The results show that
complete in vitro motility assay systems with surface-adsorbed
myosin motor fragments (heavy meromyosin, HMM), actin
ﬁlaments, and ATP can be readily stored at  20 C for at least
a month without a loss of function. This was achieved without
cumbersomeproceduressuchasfreezinginliquidnitrogenorthe
use of expensive equipment (e.g.,  80 C freezers or lyophiliza-
tion equipment). The general mechanisms for the long-term
functional preservation of surface-immobilized delicate protein
nanomachines are discussed. Our ﬁndings unfold new possibi-
lities for portable molecular-motor-based nanodevices as well as
for new developments toward the optimized storage of other
proteins with complex function.
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ABSTRACT:Theeﬀectiveandsimplelong-termstorageofcomplexfunctionalproteinsis
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substitutes microﬂuidics and forms the basis for novel detection schemes. Importantly,
therefore, we here describe that delicate heavy meromyosin (HMM)-based nanodevices
(HMM motor fragments adsorbed to silanized surfaces and actin bound to HMM) fully
maintain their function when stored at  20 C for more than a month. The mechanisms
for the excellent preservation of acto-HMM motor function upon repeated freeze thaw
cyclesarediscussed.Theresultsareimportanttothefuturecommercialimplementationof
motor-based nanodevices and are of more general value to the long-term storage of any
protein-based bionanodevice.7109 dx.doi.org/10.1021/la201081w |Langmuir 2011, 27, 7108–7112
Langmuir ARTICLE
’EXPERIMENTAL SECTION
The myosin motor fragment, heavy meromyosin (HMM, chymo-
tryptically cleaved myosin), and actin ﬁlaments were obtained from
rabbit fast skeletal muscle.
4,5 Actin was ﬂuorescently labeled using
tetramethylrhodamineisothiocyanate-phalloidin (TRITC-phalloidin).
5
Glass slides were silanized with trimethylchlorosilane (TMCS) and
mountedinaﬂowcellforinvitromotilityassay(IVMA)experiments
5,21
with incubation steps as follows: (1) HMM (120 μg/mL, 2 min), (2)
bovine serum albumin (BSA, 1 mg/mL), (3) nonﬂuorescent blocking
actin (1 μM, to block rigor heads), (4) TRITC-labeled actin ﬁlaments,
and (5) assay solution (aMC130, ionic strength 130 mM, 1 mM
MgATP, and 0.6% methylcellulose). Between steps 3 and 4, the ﬂow
cell was rinsed with solution a40 (1 mM ATP, ionic strength 40 mM)
followed by solution r65 (no ATP, ionic strength 65 mM). Rinsing with
solution r65 was employed between steps 4 and 5. (See the Supporting
Informationforadetailedcompositionofsolutions.)Themotilityassays
were performed at a temperature of 27.6 ((1.0) C.
Forthestorageofmotilityassaysbyfreezing,ﬂowcellswereplacedin
a regular  20 C freezer directly after observation in the microscope
without washing away the ATP-containing assay solution (except in
somecases,asindicatedbelow).Afterperiodsoffreezing,ﬂowcellswere
thawed at room temperature (approximately 20 C) for a few minutes
before the observation of in vitro motility. After a ﬁrst observation, ﬂow
cells were rinsed with r65 solution and then incubated with new labeled
actin, r65 solution and aMC130 assay solution.
The actin ﬁlaments were imaged using an inverted epiﬂuorescence
microscope (Nikon Eclipse TE300). Data was acquired using a CCD
camera and analyzed using a MATLAB-based algorithm.
23 GraphPad
Prism software was used for graphic representation and statistical
analysis by means of a paired or unpaired (two-tailed) t test as
appropriate. Data are given as the mean ( standard error of the mean
(SEM).
’RESULTS AND DISCUSSION
The HMM-propelled actin ﬁlament motility was maintained
after the freezing and thawing of whole ﬂow cells that contained
all of the components of the IVMA (Experimental Section).
Whentheﬂowcellhadbeenfrozenwithbothactinﬁlamentsand
anATP-containingassaysolutionandstoredat 20Cforupto
30 days,motilitywasresumed afterthawingwithout theaddition
of new assay solution. This is exempliﬁed in Figure 1A C
(Supporting Information, Movie 2). However, for quantitative
comparison to the prefreezing conditions, it was important to
avoid complications attributed to photobleaching, the consump-
tion of ATP, and the accumulation of possible toxic products
(e.g., gluconic acid due to the antibleaching mixture) during the
ﬁrst observation in the ﬂuorescence microscope (before free-
zing). We therefore added a new assay solution and new actin
ﬁlaments prior to quantitative measurements (Figure 1C). It can
be seen in Figure 2 that both the sliding velocity and the fraction
of motile ﬁlaments were similar to the values before freezing (no
signiﬁcant diﬀerence; p = 0.08 (velocity), p = 0.13 (fraction
motile)). Data from diﬀerent experiments was pooled in a single
diagram because there was no apparent diﬀerence between ﬂow
cellskept frozen fordiﬀerent timeperiods (upto30days). Thus,
motility was maintained for more than 1 month of freezing
without a noticeable decay over this time period (Figures 3 and
4). In contrast to what was reported for lyophilization and
critical-point drying
20 and subsequent reconstitution of the
kinesin microtubule motility assays, we did not observe any
appreciablefreeze thaw-inducedvariabilityinfunctionbetween
diﬀerentregionsofaﬂowcell.Becausewedidnottestlyophiliza-
tion or other drying methods, these approaches might not be
ideal for actomyosin (cf. ref 24).
Surprisingly,agivensurfacewithimmobilizedHMMcouldbe
taken through more than one freeze thaw cycle (at least two)
without substantial deterioration of the motility quality. Even
after three cycles and altogether 60 days of storage at  20 C,
motility remained with 25% motile ﬁlaments (68% motile in
control before freezing) and some ﬁlaments moving at a similar
velocity as in the control experiments (Supporting Information,
Movie 4). That there is progressive deterioration with repeated
freeze thaw cycles is not surprising because several stresses on
the proteins are associated with the physical-chemical changes
during the freezing and thawing processes per se,
25,26 suggesting
Figure 2. Eﬀects of one freeze thaw cycle on the quality of HMM-
propelled actin ﬁlament motility. Data from ﬁve diﬀerent experiments.
The control velocity was 5.97 ( 0.63 μm/s, and the control fraction of
motile ﬁlaments was 0.74 ( 0.04. The duration of the freezing period
varied between 4 and 30 days (average 16.00 days) without an appreci-
ablediﬀerenceintheeﬀectonmotilityoverthisperiod.Errorbars:SEM.
Figure 1. Actin ﬁlament path traces are integrated for 10 s: (A) the ﬂow cell before freezing (same sequence as shown in Movie 1 in the Supporting
Information),(B)thesameﬂowcellafterhavingbeenfrozenfor17daysandthawedwithoutaddinganynewsolution(thesameasinMovie2),and(C)
thesameﬂowcellafteraddingnewactinandATP-containingsolution(thesameasinMovie3).Whitebars,10μm.Yellowpartsofthetracesindicatethe
ﬁlament position 0, 3.2, and 6.8 s after the onset of recording.7110 dx.doi.org/10.1021/la201081w |Langmuir 2011, 27, 7108–7112
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that these, rather than the storage at  20 C, are most detri-
mental to function. Therefore, it also seems likely that storage at
 20 C should be possible for a considerably longer time than
that demonstrated here.
Experiments were performed (Figure 3) to investigate the
importance of diﬀerent components in the standard IVMA assay
incubation for the maintenance of actin motility after a free-
ze thaw cycle. Five diﬀerent conditions were tested: Flow cells
frozen (i) with ATP-containing assay solution and incubated
with all other components (þATP), (ii) with all components
except BSA (-BSA), (iii) with all components except blocking
actin (-block.act.), (iv) without ATP solution (rinsed after
checking the control actin motility) but otherwise incubated
withallcomponents(-ATP), andﬁnally(v)withallcomponents
except BSA and blocking actin (-ATP, -BSA, -block.act.). The
results (Figure 3) show no clear loss of motility in any of these
cases uponstorage at 20C.(However,itshouldbenotedthat
the omission of blocking actin led to a low fraction of smoothly
moving ﬁlaments (cf. Kron et al.;
5 Homsher et al.
27) both before
freezing (i.e., under control conditions) and after freezing. This,
in turn, led to very few ﬁlaments analyzed with respect to sliding
velocity in both cases as a result of the stringent criteria imposed
by the automatic analysis system (e.g., with the requirement of a
coeﬃcient of variation (CV) of the frame-to-frame velocity of
<0.20). We therefore also performed a manual analysis of the
case without blocking actin and BSA in Figure 3B. With this
approach, ﬁlaments were tracked using the computer mouse,
andtheinclusionofmoreerraticallymovingﬁlaments(CV<0.5)
was possible. Importantly, this analysis gave results con-
sistent with those based on the automatic analysis of smoothly
movingﬁlaments(CV<0.2).Thus,databasedonﬁlamentpaths
with CV < 0.50 gave a velocity of 7.86 ( 0.27 μm/s
before freezing (n = 18) and 7.15 ( 0.39 μm/s after freez-
ing (n = 26), a diﬀerence that was not statistically signiﬁcant
(p = 0.158)).
For comparison, we also investigated the storage of the
motility assay ﬂow cells (containing all of the components of
the IVMA) in a cold room at 4 C (Figure 4). Diﬀerent con-
ditionsweretested:(1)control,(2)0.3Msucrose(tocounteract
unfolding),(3)20mMPMSF(proteaseinhibitor)and(4)3mM
NaN3 (antibacterial). No appreciable diﬀerence was observed
among the diﬀerent conditions (Figure 4), but in all ﬂow cells,
the actin ﬁlament velocity was reduced to half the control value
after 5 to 14 days.
To summarize the above ﬁndings, HMM-propelled actin
ﬁlament sliding was very well preserved when ﬂow cells were
subjected to up to two freeze thaw cycles. This shows that the
complex actomyosin motor system fully maintains its function
under these conditions. This, in turn, relies on the maintenance
of the structural integrity of the dynamic
28 and proteolysis-
sensitive
4 actin ﬁlaments. It also relies on the maintained cap-
ability of the majority of the myosin motor domains to bind to
actin and undergo complex sequences of structural changes that
lead to the propulsion of actin ﬁlaments coupled to diﬀerent
steps in the turnover of ATP
29 on the myosin active site.
Moreover, our results suggest that neither the surface immobi-
lization of HMM nor the HMM surface density is appreciably
altered by the freeze thaw cycles (and several rinsing and
incubation steps).
9,30 33 We can draw this conclusion because
Figure3. Eﬀectofinvitromotilityassayincubationconditionsonmotilityqualityafterstorage.(A)Flowcellsfrozenfor6days.(B)Flowcellsfrozenfor
30 days. In both A and B, the ﬂow cells were subjected to only one freeze thaw cycle. Bars show the velocity data (smooth bars) and the fraction of
motileﬁlaments(stripedbars)ofﬁvediﬀerentﬂowcellstreatedindiﬀerentways(showninthexaxes;seethetextforafurtherexplanation).Brightbars
show data for the control ﬂow cells (day 0), and dark bars show data after the freeze thaw cycle. Error bars: SEM. Numbers in parentheses give the
number of ﬁlaments from which the average sliding velocity was obtained by automatic tracking. One criterion for inclusion in the analysis was a
coeﬃcient of variation of the frame-to-frame velocity of <0.2. (See the text.) The fraction of motile ﬁlaments with error bars was obtained by observing
three diﬀerent areas of the ﬂow cell.
Figure 4. Time series of normalized velocity. Results for ﬁve diﬀerent
ﬂow cells are shown, four of which were kept at 4 C under diﬀerent
conditions:control(black),0.3Msucrose(red),20mMPMSF(green),
or 3 mM NaN3 (blue) and another ﬂow cell (orange) was frozen at
 20 C and thawed for every observation.7111 dx.doi.org/10.1021/la201081w |Langmuir 2011, 27, 7108–7112
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the velocity of actin propulsion by low-duty-ratio myosin II
motors(incontrasttomicrotubulepropulsionbyhigh-duty-ratio
kinesin
34) is known
33,35 to be quite sensitive to the density of
appropriately oriented HMM molecules on the surface. It is also
important to view the results in the context of evidence
5,36 that
the mode of storage of HMM in solution prior to motility assays
has critical eﬀects on the velocity and/or the fraction of motile
ﬁlaments.Thelattervariablesaresensitivenotonlytothemyosin
head density but even more to the presence of damaged myosin
heads.
37 Our results suggest that, in contrast to the freezing of
HMM in solution, freezing after surface immobilization gives
excellent preservation of actomyosin function upon storage
at  20 C and for up to two freeze thaw cycles. Considering
the complexity of the system, this degree of preservation might
seem unexpected because proteins tend to degrade and lose
activity as a result of freeze thaw cycles for a variety of
stresses.
1,2,38 These include cold denaturation, freeze concentra-
tion (with osmotic gradients, local changes in pH, and local
crystallization of solutes), and ﬁnally the eﬀects of ice formation,
suchassurface-induceddenaturation.
38WithregardtoHMM,in
particular, it has been indicated that freezing in solution
at  20 C for later use in the IVMA is not advisible, even if
glycerol is added as a cryoprotecting agent.
36,39 This may be
understood because some regions of the HMM molecule exhibit
conformational instability (cf.ref 6) whereas other regions are
sensitive to oxidation. The good preservation of function in the
presentworkmay,toasubstantialdegree,beattributedtofactors
related to the surface immobilization of the proteins. One
important factor may be the high local concentration at the
surfacebecauseithasbeenshownthatafterfreezingandthawing
in solution a higher concentration of several proteins induces a
higher recovery of activity.
40 Whereas HMM is adsorbed on
TMCSsurfacesinadistributionofdiﬀerentconformations,
30the
myosin heads will tend to oscillate thermally within 40 nm from
the surface.
30 With the HMM incubation concentration of
120 μg/mL, as in the present work, one would expect the
adsorption of >5000 HMM molecules/μm
2 corresponding to
anHMMconcentrationof∼0.2mM(∼70g/L)inalayerwithin
40 nm from the surface. This is similar to the protein concentra-
tion in blood plasma. In addition to the eﬀect attributed to high
protein concentration in the HMM layer, it is also likely that the
mode of adsorption of HMM is important with the heads
generally tens of nanometers from the TMCS surface.
30 Finally,
an additional eﬀect related to surface immobilization is the
presence of unstirred layers at surfaces that will minimize shear
stresses on the proteins. The dominating HMM head conforma-
tion (diﬀerent in the presence and absence of ATP) and the
presence and absence of actin did not seem to be critical to long-
term storage. However, the data in Figure 3 indicate a tendency
toward reduced motility quality after storage in the absence of
incubation with BSA and blocking actin. The inclusion of these
incubation steps may thus be advisible and consistent with
expectations forenhanced protein stability withfurther increases
in the protein concentration close to the surface. We performed
the experiments in silanized ﬂow cells with a local physical
environment (with respect to solutions and surface substrates)
that are suitable for future nanodevices (cf. refs 9 and 32). One
mayconsiderusingsilaneswithlongeralkylchainstoincreasethe
surfacehydrophobicityfurther,withthepotentialforadditionally
increased adsorption of proteins.
41 If such increased adsorption
had been seen for HMM, this might further increase the stability
during freezing and thawing. However, under the present HMM
incubation conditions, the HMM density on TMCS surfaces is
close to that of a packed monolayer. (See above and ref 30.)
Moreover, it has been shown
42 that increased hydrophobicity
above that on TMCS-derivatized surfaces (contact angle ∼70
o)
isassociatedwithalowerHMM-propelledactinvelocity.Indeed,
a similar eﬀect (i.e., with a lower velocity) was observed on
surfacessilanizedusingchlorosilaneswithlongersidechains.
31In
these cases, the contact angle was actually lower than 70
probably because of steric eﬀects of the side chains that were
believed to limit the degree of silanization. To summarize the
above discussion, the chemically very simple trimethylchloro-
silanized surfaces seem to be nearly ideal for use in bionanode-
vices. They are readily nanopatterned
9,43 and give very repro-
ducible high-quality motility
21,31,32 close to room temperature,
and as shown here, the preservation of actomyosin function
during freeze thaw cycles is excellent. In this connection, it is
important to emphasize that the experiments were performed in
the simplest possible way (i.e., by directly freezing the ﬂow cells
subsequenttoinitialobservationandthenthawingthematroom
temperature). There would thus be substantial potential for
further optimization of the conditions (e.g., the addition of
polyols and/or other cryoprotectants
2 and appropriate titrations
of the freezing and thawing rates
38). The exact process of ice
formation (e.g., the freezing point
44) seems to vary with the
hydrophobicity of the surface (e.g., the freezing point on TMCS
surfaces would be expected to be intermediate between those of
hydrophilic and more strongly hydrophobic surfaces). This may
be important to consider in future eﬀorts to optimize the storage
conditions. The excellent preservation without optimization and
evidence that the freeze thaw cycles rather than the storage
itself is detrimental suggest that surface-immobilized actomyo-
sin-based nanodevices can be readily stored at  20 C for
a longer time than observed here (i.e., considerably more than
1 month).
’CONCLUSIONS
We have demonstrated that the long-term storage of myosin-
based nanodevices is possible at  20 C( e . g . ,u s i n ga n
ordinary household freezer). This ﬁnding reaﬃrms the possi-
bility of using such nanodevices at remote locations (e.g., in
point-of-care diagnostics because no expensive or sophisti-
cated laboratory equipment is required for storage). The
method of storage may also be useful in high-throughput
studies of actomyosin function (e.g., for drug-discovery
applications
9 or other routine investigations). Moreover, the
results may be possible to extrapolate to the storage of other
complex protein nanomachines. Thus, it may be of interest to
considerstorageat 20Cafterimmobilizationoftheproteins
to biosensor surfaces or, alternatively, to nanoparticles or
liposomes in solution.
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